Welcome to our dedicated page for Sunshine Biopharma SEC filings (Ticker: SBFM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sunshine Biopharma Inc. filings document the reporting record of a public pharmaceutical company with Canadian generic-drug operations and proprietary oncology and antiviral development programs. Form 8-K disclosures cover operating results, material events, warrant solicitation arrangements, auditor changes, officer transitions and shareholder actions affecting common-stock matters.
Proxy and annual-meeting materials describe board elections, board committees, corporate governance, executive compensation, principal shareholders, related-party transactions, auditor ratification and equity incentive plan matters. The company’s filing record also includes late-filing notices for annual reports and capital-structure disclosures involving outstanding warrants and potential stock-split authority.
Sunshine Biopharma (SBFM) will hold its 2025 virtual annual meeting on December 11, 2025 to vote on three items: elect five directors, ratify M&K CPAS, PLLC as auditor, and amend the 2023 Equity Incentive Plan to increase shares authorized for issuance from 1,661 to 683,000.
The record date is October 17, 2025, with 4,905,945 common shares and 130,000 Series B Preferred outstanding. Each Series B Preferred share carries 1,000 votes, and all Series B shares are held by the CEO, concentrating voting power. The Board recommends voting FOR all proposals.
Auditor history was addressed: following the SEC’s settled order permanently barring BF Borgers from practicing before the SEC, the company dismissed Borgers in 2024, engaged Bush & Associates, and on September 24, 2025 appointed M&K CPAS, PLLC. Executive agreements disclose severance terms, including $14,000,000 for the CEO upon certain terminations. Pay-versus-performance data shows 2024 net loss of $(5,134,116) and a total shareholder return of (99.9%) based on a $1.00 investment benchmark.
Sunshine Biopharma Inc. reported a change in its independent auditor. Effective September 24, 2025, the company dismissed Bush & Associates CPA LLC as its independent registered public accounting firm and engaged M&K CPAS, PLLC as its new auditor. The board of directors and audit committee approved this decision by unanimous consent.
The company states that for the fiscal years ended December 31, 2023 and 2024, and through September 24, 2025, there were no disagreements with Bush & Associates on accounting principles, financial statement disclosure, or audit procedures, and no reportable events under SEC rules. Bush & Associates’ prior audit reports did not contain adverse opinions, disclaimers, or qualifications. Sunshine Biopharma has requested a letter from Bush & Associates to the SEC regarding these disclosures and plans to file it by amendment once received.